Valuation: Acrux Limited

Market Cap 6.27M 4.45M 3.84M 3.61M 3.28M 6.17M 425M 42.29M 16.54M 213M 16.7M 16.33M 708M P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 9.05M 6.41M 5.54M 5.2M 4.73M 8.9M 613M 60.98M 23.84M 307M 24.08M 23.55M 1.02B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day+141.43%
3 months-2.03%
6 months+275.56%
Current year+4.00%
1 week 0
Extreme 0.0033
0.03
1 month 0
Extreme 0.0033
0.03
Current year 0
Extreme 0.0033
0.03
1 year 0
Extreme 0.001
0.05
3 years 0
Extreme 0.001
0.06
5 years 0
Extreme 0.001
0.1
10 years 0
Extreme 0.001
0.28
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 15/02/2015
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
+141.43%-.--% - - 4.18M
-0.10%-0.77%+17.58%+70.16% 48.43B
-3.26%-5.31%+52.47%+114.13% 39.72B
-0.60%-0.94%-7.29%+17.35% 12.25B
-2.75%+1.88%+14.81%+76.92% 11.84B
-0.58%-0.77%+29.90%+135.00% 9.06B
+1.56%+5.52%+23.69%+41.38% 7.57B
+0.52%+2.08%+42.23%-13.42% 7.18B
-0.07%+1.72%+13.39%+190.65% 6.84B
-2.51%-3.14%-30.53%+23.54% 5.77B
Average +13.36%+1.46%+17.36%+72.86% 16.52B
Weighted average by Cap. -1.20%+1.00%+24.83%+80.29%

Financials

2024 2025
Net sales 5.09M 3.61M 3.12M 2.93M 2.66M 5.01M 345M 34.32M 13.42M 173M 13.55M 13.26M 574M 1.19M 844K 729K 685K 623K 1.17M 80.67M 8.02M 3.14M 40.4M 3.17M 3.1M 134M
Net income -5.8M -4.11M -3.55M -3.34M -3.03M -5.71M -393M -39.1M -15.29M -197M -15.44M -15.1M -654M -5.94M -4.21M -3.64M -3.42M -3.11M -5.85M -403M -40.08M -15.67M -202M -15.82M -15.48M -671M
Net Debt 759K 538K 465K 437K 397K 747K 51.45M 5.12M 2M 25.77M 2.02M 1.98M 85.62M 2.77M 1.97M 1.7M 1.59M 1.45M 2.73M 188M 18.69M 7.31M 94.1M 7.38M 7.22M 313M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume

Annual profits - Rate of surprise